Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autolus Therapeutics PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Current Liabilities
$44.7m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Current Liabilities
$39.4m
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Current Liabilities
ÂŁ65.1m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Current Liabilities
$56.4m
CAGR 3-Years
23%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Current Liabilities
ÂŁ139m
CAGR 3-Years
36%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Current Liabilities
ÂŁ150.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Total Current Liabilities?
Total Current Liabilities
44.7m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Total Current Liabilities amounts to 44.7m USD.

What is Autolus Therapeutics PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
10%

Over the last year, the Total Current Liabilities growth was -4%. The average annual Total Current Liabilities growth rates for Autolus Therapeutics PLC have been 10% over the past three years .

Back to Top